Bayer

News

Bayer gets EU approval for menopause drug Lynkuet

Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.

News

Bayer beats expectations with tougher times looming

Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

Oncology

Interview at ESMO 2025 with Nicoletta Brega and Christine Roth from Bayer

ESMO25: The importance of personalisation, with Bayer’s Dr N...

Sales & Marketing

pharmaphorum podcast Episode 212, Bayer and Veeva

Collaborating on a connected platform journey, with Alexande...

pharmaphorum speaks with Bayer's Alexander Alex and Veeva's Florian Schnappauf about Bayer's recent migration to the connected Vault CRM platform.

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

Bayer gets EU approval for menopause drug Lynkuet

Bayer beats expectations with tougher times looming

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ESMO25: The importance of personalisation, with Bayer’s Dr N...

Collaborating on a connected platform journey, with Alexande...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Bayer

Editor's Picks